Metrics as of 10/17/2026, 12:39 AM (Berlin time), refresh in progress.
Grace Therapeutics Stock
Grace Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Prashant Kohli
- Employees
- 5
- Market cap
- $31 M
- IPO
- 07/02/2012
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid…
Grace Therapeutics stock: price history
1D
-3.1%
1W
-9.1%
1M
-11.7%
6M
-58.9%
YTD
-45.4%
1Y
-41.1%
2Y
-43.6%
5Y
–
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~24% weaker price swings than usual
Ask the agents about Grace Therapeutics
Analyst assessment of Grace Therapeutics
PRICE TARGET LOW
US$4.00
CONSENSUS
US$4.00
MEDIAN
US$4.00
PRICE TARGET HIGH
US$4.00
0
STRONG BUY
2
BUY
0
HOLD
0
SELL
0
STRONG SELL
2
TOTAL · Buy
As of: 24/04/2026
Grace Therapeutics stock metrics
P/E
-1.51
P/B
0.68
EV/EBITDA
-0.66
RETURN ON EQUITY
-32.8%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
83.5%
FLOAT SHARES
13,592,067
AVG. DAILY VOLUME (30D)
139,088
Insider transactions (SEC)
Opaleye Management Inc.
Opaleye Management Inc.
Opaleye Management Inc.
Opaleye Management Inc.
Opaleye Management Inc.
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Grace Therapeutics stock
What does Grace Therapeutics do?
Grace Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Prashant Kohli, the company employs around 5 people.
The IPO was on 07/02/2012; the stock trades on NASDAQ under the ticker GRCE.
What do analysts say about Grace Therapeutics stock?
2 analysts rate the stock, the consensus is Buy (as of 24/04/2026).
The average price target is US$4.00, ranging from US$4.00 to US$4.00, with a median of US$4.00.
This is an external assessment, not a statement by Market Jury.
When does Grace Therapeutics report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly -24% stronger than usual.
Does Grace Therapeutics pay a dividend?
No, Grace Therapeutics currently does not pay a dividend.
Which stocks are comparable to Grace Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Grace Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Grace Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.